1.1. Background
CIN
CHEMOTHERAPY-INDUCED NEUTROPENIA, ADVERSE EVENTS, CROSS, CIN
Chemotherapy-induced neutropenia (CIN) is one of representative adverse events (AEs) of cytotoxic chemotherapy thatPegylated granulocyte-colony-stimulating factor (peg-GCSF) was developed to increase the half-life to 46 to 72 hours by attaching polyethylene glycol to filgrastim so that only 1 administration per cycle is necessary to prevent CIN. A single injection of peg-GCSF showed an equivalent effect to daily filgrastim therapy in a comparative study.However, approximately 13% of patients receive same-day peg-GCSF probably due to the inconvenience of providing an additional hospitalization or hospital visit for administration of the peg-GCSF.Pegteograstim is a new formulation of peg-GCSF, that was developed by Green Cross Corporation in Korea. Pegteograstim was compared with the pegfilgrastim in a 2016 phase II/III study. There was no significant difference in Gr4 CIN duration (pegteograstim 1.97 days, pegfilgrastim 1.54 days, 